ANGO Unveils New Product - Analyst Blog

AngioDynamics, Inc. (ANGO) recently launched its new product, Centros hemodialysis access catheter, in the United States. The new product uses a curved tip catheter technology and provides higher blood flow and lower recirculation. 

It has been tested that when Centros is placed in the lower portion of the superior vena cava, the curved tip of the product keeps the ports of the catheter away from the vein walls. This prevents clot formation and also stops the formation of fibrin sheathing in which a fibrous protein in the blood coats the catheter and compromises on its functioning. 

The Centros hemodialysis access catheter has superior features compared to other catheters available in the market. Preliminary studies suggest that the new product provides highly acceptable flow rates at modest negative pressure without deterioration in flow rate over seven weeks of use, even with tips positioned in the superior vena cava rather than within the atrium. 

The seven week follow-up results suggest that the flow rate for the Centros hemodialysis access catheter was 401mL/min, compared to the control group of competitive catheters at 348mL/min, with a pressure of less than 0.05. 

We think that the new product will be highly accepted by physicians as a result of their enhanced features. This in turn will boost AngioDynamics’ top-line. 

AngioDynamics is engaged in the designing, development, manufacture and marketing of therapeutic and diagnostic devices to treat peripheral vascular disease (PVD) and other non-coronary diseases. 

Presently, we are ‘Neutral’ on AngioDynamics.
Read the full analyst report on "ANGO"
Zacks Investment Research